Arine key facts
as of Oct 2026- Developer of a medication management platform designed to improve health and quality of life.
- Arine is valued at approximately $520.0M as of Oct 2026 (last reported valuation).
- It has raised $63.6M; the latest was Later Stage VC ($30.0M) in Jun 2025.
- Notable investors include MBX Capital, Town Hall Ventures, Kaiser Permanente Ventures, New Leaf Venture, 111 West Capital — 11 tracked in total.
- Status: Privately Held (backing).
Arine's last reported valuation, Jun 2025. Nothing priced has surfaced since.
- ·The complete investor list: 11 names
- ·Watch Arine: the Monday email on marks, rounds and moves
Arine funding rounds
No funding rounds for Arine are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Arine
11+Arine valuation
Arine's last reported valuation was $520 million in Jun 2025. No priced round, secondary trade or fund mark has surfaced since.
Arine investors
11 investors are on record for Arine, including MBX Capital, Town Hall Ventures, Kaiser Permanente Ventures and New Leaf Venture.
About Arine
Developer of a medication management platform designed to improve health and quality of life. The company's medication optimization platform aggregates and analyzes clinical, social, and behavioral data to identify and address gaps in patient care on behalf of payors and risk-bearing providers, enabling patients to get improved outcomes and lower costs for care.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2017
- Employees
- 200
- Website
- arine.io/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.